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Background: Lung cancer remains a leading cause of cancer incidence and mortality worldwide. Although 
Spain contributes to global statistics related to cancer, it is difficult to discern aspects linked to clinical 
presentation of the disease or molecular testing. The Thoracic Tumor Registry (TTR) was created with the 
aim of filling this gap.
Methods: Observational cohort multicenter study performed in Spain, including patients with lung 
cancer or other types of thoracic tumors undergoing active treatment or palliative care only. Enrollment 
took place between August 2016 and December 2018. The evaluation included a review of demographic, 
epidemiological, clinical and molecular data.
Results: A total of 6,600 patients diagnosed with non-small cell lung cancer (NSCLC) were recruited at 56 
Spanish hospitals. The mean age at diagnosis was 64 years. The majority of patients (80%) presented with 
advanced disease, being adenocarcinoma the most frequent histological type. Up to 86% of patients were 
current- or ex-smokers, with men starting to smoke earlier than women (average age 17.9 vs. 19.2 years). 
Sixty-seven percent of patients underwent some type of molecular testing. Mutations in EGFR and KRAS 
genes were found in 18% and 28% of patients, respectively.
Conclusions: Our findings suggest that the TTR study accurately describes the clinical reality of lung 
cancer in Spain, including useful information on smoking status as well as molecular profiling and tumor 
histology, and can therefore be used to drive improvements in health care. Social and political pressure to 
reduce tobacco consumption among the population should be reinforced, particularly among youth.
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Introduction
Lung cancer remains a leading cause of cancer incidence 
and mortality worldwide among both men and women, with 
more than 2 million newly diagnosed cases and 1.8 million 
deaths in 2018, accounting for close to 1 in 5 (18.4%) 
cancer deaths (1). Lung cancer is broadly divided into two 
categories according to its histological characteristics: small 
cell lung cancer (SCLC, ~15% of all lung cancers) and 
non-small cell lung cancer (NSCLC, ~85%). The latter 
comprises several histological subtypes, mainly squamous 
cell carcinoma, adenocarcinoma and large-cell lung cancer; 
adenocarcinoma is the most common subtype of NSCLC 
(~40%) (2,3). 
The most important risk factor for lung cancer is tobacco 
smoking, along with other environmental pollutants (4,5). 
Nevertheless, only approximately 10% of smokers develop 
lung cancer, and the disease also occurs in the absence of 
exposure to cigarette smoke (6); in this sense, several studies 
have identified a genetic susceptibility locus for lung cancer 
carcinogenesis and prognosis (7). Since these risk factors are 
highly preventable, mortality rates can be largely reduced 
through tobacco control and other population-based 
preventive strategies (8). Global numbers show a declining 
trend in the incidence and mortality rates in men, primarily 
due to decreased cigarette consumption. Among women, 
the tobacco epidemic is less advanced, and most countries 
are still observing a rising trend in incidence; only relatively 
few populations (e.g., the US and possibly the UK) are 
showing signs of decline among recent birth cohorts (1,9). 
Information from European registries, including 
treatments for lung cancer and their efficacy, as well as data 
on tobacco consumption and mutational profiles of tumors, 
is somewhat scarce. Many countries collect data on a 
national level, with the majority using a national registry for 
all cancers, but few have a data collection program for lung 
cancer in addition to a cancer registry (10). However, this 
information is of particular interest, not only because of the 
need for deeper understanding of the characteristics of lung 
cancer, both in its presentation and during treatment, but 
also to evaluate certain aspects related to health care quality. 
In this sense, information from a country like Spain, with 
universal health coverage, can provide valuable data from 
a more realistic scenario, with no bias related to private 
health insurance or patient socioeconomic status.
According to recent data from the Spanish National 
Institute of Statistics (INE), lung cancer was responsible for 
the highest number of deaths among the Spanish population 
in 2017, and for the first time was the second cause of 
cancer mortality among Spanish women, especially due to 
smoking (11); the number of deaths in 2017 increased by 
6.4% compared to the previous year, and doubled compared 
to 2003 (12). 
Until recently, the coverage of the population by cancer 
registries in Spain was limited, with no official, unified 
database for lung cancer and other thoracic tumors. To 
obtain a better picture of the epidemiology of these diseases 
in Spain, in 2016 the Spanish Lung Cancer Group (GECP) 
created the first Thoracic Tumor Registry (TTR), an 
observational, prospective cohort multicenter study that 
included patients treated for lung cancer and other thoracic 
tumors. To our knowledge, this is the first registry of its 
kind in Europe. In this paper, we present the methodology 
of the registry and the results from 6,600 patients with 
NSCLC recruited in 56 Spanish hospitals until December 
2018.
Methods
Study design
The TTR is an observational (patient registry), non-
post-authorization, prospective cohort multicenter study. 
Enrolment started in August 2016 and is still ongoing (as 
of April 23, 2019, 10,145 patients from 58 centers had been 
included in the study, 8,653 of whom had been diagnosed 
with NSCLC). The study was conducted in accordance 
with the provisions of the Declaration of Helsinki. Protocol 
approval was obtained from the institutional review 
board at each study site. The registry was approved in 
2016 by the Spanish Agency for Medicines and Medical 
Devices (AEMPS) and is registered on the ClinicalTrials.
gov database (NCT02941458). Protocol approval was 
obtained from the institutional review board of Hospital 
Universitario Puerta de Hierro Majadahonda (No. PI 
148/15).
Study sponsor
This registry was sponsored by the GECP, an independent, 
cooperative and multidisciplinary oncology group 
established in 1991, whose purpose is to promote the study 
and research of lung cancer and incorporate advances in the 
treatment of the disease into routine clinical practice. The 
GECP consists of more than 400 specialists from all over 
Spain associated with treatment and research in lung cancer, 
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mostly medical oncologists. It brings together a network 
of more than 160 public and private hospitals distributed 
throughout the Spanish territory that conduct their research 
in a coordinated manner. This infrastructure was the basis 
for establishing the TTR registry, proposed by the steering 
committee. 
Eligibility
Eligible patients included those with lung cancer or other 
types of thoracic tumors (NSCLC, SCLC, mesothelioma, 
thymic carcinoma, carcinoid cancer) undergoing active 
treatment or not treated (palliative care only), with no sex 
or age restrictions. Patients with other types of tumors and 
healthy volunteers were not admitted. 
Information retrieval
Data was collected from patient medical records using 
an electronic data capture system (EDC), where each 
research team included the information on all patients 
with lung carcinoma attended by the healthcare personnel 
of their hospital. Sociodemographic, epidemiological, 
clinical, molecular/genetic and treatment outcome (e.g., 
response rate, current status, date of death) variables 
were recorded. The information collected was classified 
into different sections: (I) patient personal history, which 
included the performance status (PS), tobacco consumption 
(including environmental exposure to tobacco smoke), 
and comorbidities; (II) family history of cancer; (III) 
diagnosis, which included the histological type and detailed 
TNM classification of the tumor (including the location 
of metastases when appropriate); (IV) treatment, which 
included information on all treatments received, including 
dates and specific characteristics (surgery, chemotherapy, 
radiotherapy); (V) disease progression; and (VI) genetic 
information (alterations of driver genes).
Statistical analysis
Descriptive statistics were performed and quantitative data 
were summarized as mean, standard deviation (SD), median, 
interquartile range (IQR), minimum, and maximum. 
Qualitative variables were summarized as frequencies in 
the entire population and percentages. Characteristics of 
two groups (early and advanced) were compared using the 
χ2 test for categorical variables. The significance level was 
established at a value of α=0.05.
Results
Patient characteristics
A total of 6,600 patients diagnosed with NSCLC were 
enrolled between August 2016 and December 2018 in 
56 hospitals of 12 Spanish autonomous regions. The median 
number of patients/month (patients/year) recruited in 2017 
and 2018 was 162 [1,900] and 402 [4,423], respectively. 
Enrolled patients were diagnosed with NSCLC from before 
2010 to 2018, with approximately 50% of them diagnosed 
in the last 3 years [2016–2018]. 
Baseline patient characteristics are shown in Table 1. 
There were significantly more males (73.4%) than females 
(26.6%). Median age at diagnosis was 64.0 years, with 
approximately 30% of patients being younger than 55 or 
older than 75 years. Regarding tobacco use, more than 85% 
of the patients diagnosed (n=5,650) were current smokers 
(n=2,611, 39.6%) or ex-smokers (n=3,039, 46.0%), and 
only 13.1% (n=866) had never smoked. The most frequent 
histological type was adenocarcinoma (n=4,208, 63.8%), 
followed by squamous cell carcinoma (n=1,826, 27.7%) 
and large cell carcinoma (n=202, 3.1%). More than 85% 
of patients presented a good PS [Eastern Cooperative 
Oncology Group (ECOG) PS of 0 or 1].
Patient characteristics according to disease stage
Median age at diagnosis was 64 years for patients with 
advanced disease and 65 for those with early-stage disease. 
As expected, most patients presented with advanced stage 
III (n=1,874, 28.4%) or IV (n=3,446, 52.2%) disease at 
diagnosis, independently of sex (63.1% and 70.6% in males 
and females, respectively). Interestingly, among those 
diagnosed with advanced disease, a progressive growth 
in the percentage of adenocarcinoma was observed over 
the years of diagnosis: 11% in ≤2012, 16% in 2013/2014, 
28% in 2015/2016 and 32% in 2017/2018. There was 
a higher number of patients with no comorbidities at 
diagnosis among those with advanced disease than among 
those with early-stage disease (63.4% vs. 36.6%, P<0.001), 
although among patients who presented comorbidities, 
the prevalence was much higher, in general, in those 
with advanced disease. Significant differences (P<0.001, 
unless otherwise indicated) were observed between the 
two groups in the prevalence of cardiopathy, dyslipidemia 
(P=0.043), chronic obstructive pulmonary disease (COPD), 
hypercholesterolemia (P=0.026), hypertension, nephropathy 
(P=0.012), obesity (P=0.007), and vasculopathy (Table 2). 
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Table 1 Baseline characteristics of the patients
Characteristic n %
Sex
Male 4,847 73.4
Female 1,753 26.6
Age at diagnosis
Mean (SD), years 63.9 (10.2)
Median [range], years 64 [21–98]
Distribution
<55 years 1,046 15.8
55–64 years 1,838 27.8
65–74 years 1,956 29.6
≥75 years 907 13.7
Unknown 853 12.9
Race
Caucasian 6,507 98.6
Other 93 1.4
Smoking status
Never smoker 866 13.1
Ex-smoker 3,039 46.0
Current smoker 2,611 39.6
Unknown 84 1.3
ECOG PS
ECOG PS 0 2,396 36.3
ECOG PS 1 3,342 50.6
ECOG PS 2 650 9.8
ECOG PS 3 158 2.4
ECOG PS 4 19 0.3
ECOG PS 5 18 0.3
Unknown 17 0.3
Stage
I 662 10.0
IA 312 4.7
IB 348 5.3
Ix 2 0.0
II 592 9.0
IIA 248 3.8
IIB 344 5.2
Table 1 (continued)
Table 1 (continued)
Characteristic n %
III 1,874 28.4
IIIA 1,041 15.8
IIIB 765 11.6
IIIC 68 1.0
IV 3,446 52.2
IVA 18 0.3
IVB 26 0.4
IVx 3,402 51.5
Other 26 0.4
Histology
Adenocarcinoma 4,208 63.8
Adenosquamous carcinoma 68 1.0
Squamous cell carcinoma 1,826 27.7
Large cell carcinoma 202 3.1
Sarcomatoid carcinoma 18 0.3
NOS/undifferentiated 151 2.3
LC neuroendocrine carcinoma 75 1.1
Carcinoid tumor 5 0.1
Other 47 0.7
ECOG PS, Eastern Cooperative Oncology Group performance 
status; LC, large cell; NOS, not otherwise specified; SD, 
standard deviation.
Likewise, the prevalence of symptoms, including cough, 
pain, dyspnea, hemoptysis, weight loss, anorexia, and 
asthenia was much higher (P<0.001) among patients with 
advanced disease (Table S1).
Although no association was found between the 
professional occupation of patients (recorded in only 20% 
of cases) and the disease stage at diagnosis (data not shown), 
differences were found according to previous exposure to 
potential carcinogenic compounds. Compared to the total 
population, a higher percentage of patients with advanced 
disease was observed among those who had been exposed 
to arsenic compounds (87.5% vs. 65.1%, P=0.020) and, to 
a lesser extent, acrylonitrile (75.0% vs. 65.1%, P=0.020); 
on the other hand, early-stage disease was more prevalent 
among patients exposed to asbestos (47.5% vs. 34.9%, 
P=0.020), radon/silica (47.4% vs. 34.9%, P=0.020) and, to 
a lesser extent, paint (38.1% vs. 34.9%, P=0.020) and diesel 
465Translational Lung Cancer Research, Vol 8, No 4 August 2019
© Translational lung cancer research. All rights reserved.   Transl Lung Cancer Res 2019;8(4):461-475 | http://dx.doi.org/10.21037/tlcr.2019.08.05
engine smoke (38.2% vs. 34.9%, P=0.020) (Table S2).
More patients with a previous history of cancer had 
early-stage disease at diagnosis than those with advanced 
disease (47.6% vs. 34.9%, P<0.001); no differences were 
found in the disease stage at diagnosis according to family 
history of prostate cancer (Table S3).
Smoking status
The majority of patients included in the study, 86.7%, 
were current smokers or ex-smokers (40.1% and 46.6%, 
respectively). Only 13.3% had never smoked (Table 3). In 
addition, almost 16% of patients were passive smokers (i.e., 
those who lived with active smokers in the last 20 years), with 
proportionally higher percentage among women (Table S4).
Smoking status according to sex
Comparing smoking status by sex, significant differences 
were observed between males and females in all groups, 
non-smokers, ex-smokers and current smokers (P<0.001). 
Table 2 Patient characteristics and comorbidities according to the initial stage of the disease
Characteristic
Total (n=6,574) Early disease (n=2,295) Advanced disease (n=4,279)
P value
n % n % n %
Sex <0.001
Male 4,830 73.5 1,782 36.9 3,048 63.1
Female 1,744 26.5 513 29.4 1,231 70.6
Age <0.001
Mean (SD), years 63.9 (10.2) 65.0 (9.7) 63.3 (10.4)
Median [P25–P75], years 64 [57–71] 65 [59–72] 64 [56–71]
Comorbidities <0.001
Unknown 765 11.6 219 28.6 546 71.4
No 1,072 16.3 342 31.9 730 68.1
Yes 4,737 72.1 1,734 36.6 3,003 63.4
Asthma 96 1.5 29 30.2 67 69.8 0.388
Cardiopathy 834 12.7 342 41.0 492 59.0 <0.001
Diabetes mellitus 1,081 16.4 400 37.0 681 63.0 0.116
Dyslipidemia 1,590 24.2 589 37.0 1,001 63.0 0.043
COPD 1,221 18.6 579 47.4 642 52.6 <0.001
Ex alcoholism 346 5.3 115 33.2 231 66.8 0.524
Hepatitis 100 1.5 30 30.0 70 70.0 0.342
Hypercholesterolemia 485 7.4 192 39.6 293 60.4 0.026
Hypertension 2,394 36.4 923 38.6 1,471 61.4 <0.001
Nephropathy 152 2.3 68 44.7 84 55.3 0.012
Obesity 261 4.0 112 42.9 149 57.1 0.007
Depressive syndrome/anxiety 409 6.2 139 34.0 270 66.0 0.708
Tuberculosis 92 1.4 35 38.0 57 62.0 0.511
Vasculopathy 362 5.5 156 43.1 206 56.9 0.001
Other 2,457 37.4 867 35.3 1,590 64.7 0.630
COPD, chronic obstructive pulmonary disease; SD, standard deviation.
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The percentage of non-smokers was much higher in 
females (37.7%) than in males (4.5%), while the percentage 
of ex-smokers was much higher in males (53.4%) than in 
females (27.9%), as was the percentage of current smokers 
(42.1% vs. 34.4%, respectively). These sex differences were 
maintained throughout all the years of diagnosis. In males, 
a rapidly growing trend in the number of patients who were 
active smokers was observed from 2015 to 2018, along with 
an opposite downward trend in the number of ex-smokers; 
the low percentage of males who never smoked remained 
stable throughout the period analyzed. In females, a rapid 
decline in the number of patients who never smoked was 
observed from 2011 onwards, along with a continuous rise 
in the number of current smokers; although much higher 
than in males, the percentage of ex-smokers remained more 
or less stable during the period analyzed (Table 3). 
Age of onset of smoking
The age of onset of smoking was recorded in 2,707 patients 
(47.9% of total current smokers and ex-smokers), with the 
average being 18.2 years in the total population. There 
were significant differences (P<0.001) between males and 
females, with males being earlier to start smoking (mean 
age 17.9 years; 95% CI: 17.6–18.2) than females (mean age 
19.2 years; 95% CI: 18.5–19.8) (Figure 1A). The differences 
in the average age of onset of smoking between sexes 
remained more or less stable throughout all the years of 
diagnosis (Figure 1B).
Smoking status according to disease stage
No association was observed between the smoking status, 
active or passive, and the initial stage of the disease. In 
all subgroups, the percentage of patients presenting with 
advanced disease was significantly higher (active smoking, 
P<0.001; passive smoking, P=0.003) than that of patients 
with early disease (Table 4).
Biomarker profiling of tumors
A total of 4,456 patients (67.5%) underwent some type 
of molecular testing for biomarker analysis, including 
epidermal growth factor receptor (EGFR), anaplastic 
lymphoma kinase (ALK), Kirsten rat sarcoma viral 
oncogene homolog (KRAS), B-RAF proto-oncogene, 
serine/threonine kinase oncogene (BRAF), human 
epidermal growth factor receptor type 2 (HER2), ROS 
proto-oncogene 1, receptor tyrosine kinase (ROS1), 
fibroblast growth factor receptor type 1 (FGFR1), T
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programmed death-ligand 1 (PD-L1), proto-oncogene 
tyrosine-protein kinase receptor Ret (RET), and tyrosine-
protein kinase MET/hepatocyte growth factor receptor 
(MET). EGFR mutational profiling was the most frequent 
test, performed in about 60% of the population. Mutations 
in EGFR were detected in 18.1% of patients, including in-
frame deletions in exon 19 (53.7%), point mutations in exon 
21 (30.0%), and T790M mutation in exon 20 of the kinase 
domain (15.2%), among other mutations (15.2%). KRAS 
mutations were detected in 28.4% of patients (Table 5). 
The total percentage of biomarker characterization 
increased from 57.9% before 2013 to 73.7% in 2017/2018. 
Particularly relevant in this period was the increase in 
the percentage of characterization of PD-L1 (from 5.5% 
to 51.8%) and ALK (from 35.2% to 54.1%) (Table 6). 
In general, the mutational profile of advanced, stage IV 
tumors (n=3,446, 52.2%) was rather similar to that of 
the total set of tumors, regardless of the disease stage 
(Table S5). There were also differences in the percentage 
of biomarker characterization in advanced tumors 
(adenocarcinoma) according to the year of diagnosis. 
A progressive increase from before 2013 to 2017/2018 
was observed in the percentage of ALK characterization 
(immunohistochemistry, IHC), from 30.7% to 64.8% 
(P<0.001) and ROS1 (fluorescence in situ hybridization, 
FISH), from 6.7% to 20.7% (P<0.001). In addition, 
Figure 1 Age of onset of smoking. (A) The age of onset of smoking was recorded in 2,707 patients (47.9% of total current smokers and ex-
smokers), with the average being 18.2 years in the total population. There were significant differences (P<0.001) between males and females, 
with males being earlier to start smoking (mean age 17.9 years; 95% CI: 17.6–18.2) than females (mean age 19.2 years; 95% CI: 18.5–19.8). 
(B) The differences in the mean age of onset of smoking between sexes remained more or less stable throughout all the years of diagnosis.
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Table 4 Smoking status according to the initial stage of the disease
Variable
Total (n=6,574) Early disease (n=2,295) Advanced disease (n=4,279)
P value
n % n % n %
Smoking status <0.001
Never smoker 865 13.2 251 29.0 614 71.0
Ex-smoker 3,028 46.1 1,208 39.9 1,820 60.1
Current smoker 2,599 39.5 807 31.1 1,792 68.9
Unknown 82 1.2 29 35.4 53 64.6
Passive smoking 0.003
No 870 13.2 343 39.4 527 60.6
Yes 1,039 15.8 377 36.3 662 63.7
Unknown 4,665 71.0 1,575 33.8 3,090 66.2
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Table 5 Molecular profiling of tumors at diagnosis
Biomarker n %
Any biomarker
No 2,144 32.5
Yes 4,456 67.5
ALK (IHC)
Not performed 4,209 63.8
Performed 2,391 36.2
Negative 2,289 95.7
Positive 102 4.3
ALK (FISH)
Not performed 5,746 87.1
Performed 854 12.9
Not translocated 757 88.6
Translocated 97 11.4
Table 5 (continued)
Table 5 (continued)
Biomarker n %
ALK (RNA)
Not performed 6,545 99.2
Performed 55 0.8
Not detected 53 96.4
Detected 2 3.6
KRAS
Not performed 6,104 92.5
Performed 496 7.5
Not detected 355 71.6
Detected 141 28.4
BRAF
Not performed 6,059 91.8
Performed 541 8.2
Not detected 523 96.7
Detected 18 3.3
HER2 (mutated)
Not performed 6,569 99.5
Performed 31 0.5
Not detected 29 93.5
Detected 2 6.5
HER2 (IHC)
Not performed 6,578 99.7
Performed 22 0.3
Negative 21 95.5
Positive 1 4.5
HER2 (FISH)
Not performed 6,596 99.9
Performed 4 0.1
Negative 4 100.0
Positive 0 0.0
ROS1 (FISH)
Not performed 5,836 88.4
Performed 764 11.6
Not translocated 731 95.7
Translocated 33 4.3
Table 5 (continued)
a much higher percentage of positive results for ALK 
rearrangements (IHC) was observed before 2013, compared 
to later years. The percentage of EGFR characterization, 
although high throughout all the years of follow-up, showed 
a progressive increase from 84.8% before 2013 to 92.1% in 
2017/2018 (P<0.001) (Table S6).
Discussion
In our opinion, it is essential to have information on 
patients that allows the current situation of lung cancer in 
different European regions to be compared. Although the 
EUROCARE study attempts to monitor and identify the 
survival of cancer patients in Europe, it only covers about 
1% of the population and has reported potentially important 
regional variations (13). At country level, several initiatives 
have been carried out in European countries. In England, 
for example, the National Lung Cancer Audit (NLCA) 
was established in 2004 to identify possible inequalities 
within the National Health Service and to highlight the 
potential for service improvements (14); in Denmark, the 
Danish Lung Cancer Registry (DLCR) was set up in 1991 
to improve survival and clinical management of Danish 
lung cancer patients, as well as to produce a platform for 
lung cancer research (15); and in Sweden, the National 
Quality Registry for Lung Cancer was established in 2002 
to provide information on diagnostic procedures, staging 
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methods, tumor characteristics, planned treatment, study 
participation and follow-up (16). In addition, registry-based 
studies have been published in Norway (17), France (18), 
Germany (19) and the Netherlands (20). In Spain, however, 
there has been no national hospital clinical register to date.
The TTR study reflects the current epidemiology and 
treatment of lung cancer in Spain, based on a very large 
sample size. Among the main findings, we observed that, 
at the time of diagnosis, the median age was 64 years and 
52% of patients presented with advanced stage IV disease. 
Despite the fact that the majority of cases corresponded 
to males (about 73%), females already account for around 
1 in 4 cases of lung cancer (27%), following the upward 
global trend observed in recent years (21). Data published 
in 2017 showed that, among all countries with an increasing 
incidence among women, Spain had the second highest 
average annual percentage change (8.2, 95% CI: 6.6–9.9; 
P<0.001) in the last 10 years (22).
Tobacco use was a risk factor that was present in 86% of 
our patients, with 46% being active smokers (42% among 
males and 34% among females) at the time of diagnosis, 
confirming that tobacco smoke is the main cause of this type 
of tumor (4,21). Comparing tobacco use by sex, striking 
differences were observed, with a higher percentage of male 
ex-smokers (nearly twice that of females) and a very much 
higher percentage (more than 8-fold) of female never-
smokers. The percentage of active female smokers, although 
slightly less, was dangerously close to that of males. These 
data are somewhat worrying, since, although not without 
controversy, several studies have argued that women are 
more vulnerable to tobacco carcinogens (23,24) and are 
more predisposed than men to molecular aberrations 
resulting from the carcinogenic effects of tobacco 
smoke (25). Furthermore, female smokers are more likely 
than male smokers to develop adenocarcinoma of the lung, 
and those women who have never smoked are more likely 
to develop lung cancer than men (26). Considering the 
entire study population, the average age of onset of smoking 
was 18.2 years, with males starting to smoke significantly 
earlier; however, among women, a much higher percentage 
of later onset of smoking—from 16 to 19 years old—was 
observed, supporting the concern about the dangerous 
growing tendency of women to start smoking. Additionally, 
we must take into account that passive smoking causes many 
of the same diseases as direct smoking, and is a risk factor 
for lung cancer as well as other types of cancer (27). In this 
study, and in line with this evidence, a lower percentage 
of patients with early-stage disease at diagnosis were non-
Table 5 (continued)
Biomarker n %
FGFR1
Not performed 6,587 99.8
Performed 13 0.2
Not amplified 12 92.3
Amplified 1 7.7
PD-L1
Not performed 4,837 73.3
Performed 1,763 26.7
Unknown 128 7.3
Negative 757 42.9
Positive 878 49.8
RET
Not performed 6,556 99.3
Performed 44 0.7
Not translocated 43 97.7
Translocated 1 2.3
MET
Not performed 6,474 98.1
Performed 126 1.9
Negative 116 92.1
Overexpressed 1 0.8
Amplified 9 7.1
EGFR
Not performed 2,602 39.4
Performed 3,998 60.6
Unknown 12 0.3
Not mutated 3,263 81.6
Mutated 723 18.1
Exon-19 388 53.7
Exon-21 217 30.0
T790M (+) 110 15.2
T790M (–) 29 4.0
Other type 110 15.2
ALK, anaplastic lymphoma kinase; BRAF, B-RAF proto-oncogene, 
serine/threonine kinase oncogene; EGFR, epidermal growth factor 
receptor; FISH, fluorescence in situ hybridization; FGFR1, fibroblast 
growth factor receptor type 1; HER2, human epidermal growth 
factor receptor type 2; IHC, immunohistochemistry; KRAS, Kirsten 
rat sarcoma viral oncogene homolog; MET, tyrosine-protein kinase 
MET/hepatocyte growth factor receptor; PD-L1, programmed 
death-ligand 1; RET, proto-oncogene tyrosine-protein kinase 
receptor; RNA, ribonucleic acid; ROS1, ROS proto-oncogene 1 
receptor tyrosine kinase.
470 Provencio et al. The Spanish Thoracic Tumors Registry (TTR)
© Translational lung cancer research. All rights reserved.   Transl Lung Cancer Res 2019;8(4):461-475 | http://dx.doi.org/10.21037/tlcr.2019.08.05
Table 6 Molecular profiling of tumours according to year of diagnosis
Biomarker
All years (n=5,755) ≤2012 (n=916) 2013–2014 (n=1,066) 2015–2016 (n=1,679) 2017–2018 (n=2,094)
P value
n % n % n % n % n %
Any biomarker <0.001
Yes 4,456 77.4 530 57.9 720 67.5 1,138 67.8 1,544 73.7
ALK (IHC) <0.001
Performed 2,164 37.6 217 23.7 351 32.9 688 41.0 908 43.4
Positive 93 4.3 15 6.9 18 5.1 25 3.6 35 3.9
ALK (FISH) 0.002
Performed 683 11.9 103 11.2 142 13.3 230 13.7 208 9.9
Translocated 95 13.9 13 12.6 26 18.3 33 14.3 23 11.1
ALK (RNA) 0.150
Performed 49 0.9 3 0.3 9 0.8 20 1.2 17 0.8
Detected 2 4.1 1 33.3 1 11.1 0 0.0 0 0.0
KRAS <0.001
Performed 462 8.0 52 5.7 97 9.1 148 8.8 165 7.9
Detected 135 29.2 10 19.2 33 34.0 45 30.4 47 28.5
BRAF <0.001
Performed 502 8.7 83 9.1 103 9.7 134 8.0 182 8.7
Detected 17 3.4 3 3.6 2 1.9 6 4.5 6 3.3
HER2 (Mutated) <0.001
Performed 31 0.5 7 0.8 17 1.6 7 0.4 0 0.0
Detected 2 6.5 0 0.0 2 11.8 0 0.0 – –
HER2 (IHC) –
Performed 22 0.4 4 0.4 10 0.9 6 0.4 2 0.1
Positive 1 4.5 0 0.0 0 0.0 0 0.0 1 50.0
HER2 (FISH) –
Performed 3 0.1 1 0.1 0 0.0 2 0.1 0 0.0
Positive 0 0.0 0 0.0 – – 0 0.0 – –
ROS1 (FISH) <0.001
Performed 691 12.0 84 9.2 97 9.1 212 12.6 298 14.2
Translocated 31 4.5 5 6.0 9 9.3 8 3.8 9 3.0
FGFR1 –
Performed 12 0.2 2 0.2 4 0.4 4 0.2 2 0.1
Amplified 1 8.3 0 0.0 1 25.0 0 0.0 0 0.0
Table 6 (continued)
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passive smokers. It should be noted that a higher than 
expected percentage of passive smokers was found among 
females. In our opinion, and in view of these results, the 
social and political pressure to reduce tobacco consumption 
among the population should be reinforced, particularly 
among youth. 
Our data highlight the change of histological subtype 
presentation already suggested in EUROCARE studies (13). 
Although these studies have limitations derived from the 
high number of patients with non-specific histological 
subtypes and lack of diagnostic uniformity between 
different countries, it seems clear that there is an increasing 
frequency of adenocarcinoma (26,28,29), which was 
also the subtype most frequently observed in the TTR 
study. Since the 1970s in the US, adenocarcinoma as a 
percentage of all lung carcinomas has nearly doubled in 
men and increased from ~25% to ~33% in women, among 
whom adenocarcinoma has long been the most commonly 
diagnosed histological type (30). Although it has not been 
fully demonstrated, the decrease in tars and increase in 
nitrosamines in filtered cigarettes has been suggested as 
the cause of the recent change of dominant cell type from 
squamous cell to adenocarcinoma (31).
Regarding the presentation of the disease at diagnosis, 
our data were comparable to those from registries from the 
US, Canada and Australia, as well as European countries, 
such as the UK, Denmark, Norway and Sweden. However, 
it is worth noting the earlier diagnosis in our country, at 
mean age 64 vs. ~70 years in most of these countries, which 
is probably due to more complete, globalized healthcare 
coverage (32-35).
The molecular characterization of lung cancer has 
considerably changed the classification and treatment 
of these tumors, becoming an essential component of 
pathologic diagnosis and oncologic therapy decisions (36). 
In this study, just over two thirds of patients (67.5%) 
underwent molecular testing, reaching the significant 
percentage of 81.4% in patients with stage IV disease. It is 
worth highlighting not only the high percentage of EGFR 
mutation testing, but also the progressive and rapid increase 
in some biomarker profiling, as was the case of PD-L1 
expression and determination of ALK rearrangements.
Table 6 (continued)
Biomarker
All years (n=5,755) ≤2012 (n=916) 2013–2014 (n=1,066) 2015–2016 (n=1,679) 2017–2018 (n=2,094)
P value
n % n % n % n % n %
PD-L1 <0.001
Performed 1,514 26.3 50 5.5 118 11.1 262 15.6 1,084 51.8
Positive 768 50.7 21 47.7 54 45.8 103 39.3 590 54.4
RET <0.001
Performed 44 0.8 36 3.9 2 0.2 3 0.2 3 0.1
Translocated 1 2.3 1 2.8 0 0.0 0 0.0 0 0.0
MET <0.001
Performed 124 2.2 2 0.2 15 1.4 89 5.3 18 0.9
Overexpressed/
amplified
10 8.1 0 0.0 4 26.7 6 6.7 0 0.0
EGFR 0.003
Performed 3,521 61.2 511 55.8 671 62.9 1,050 62.5 1,289 61.6
Mutated 642 18.2 109 21.3 126 18.8 190 18.1 217 16.8
ALK, anaplastic lymphoma kinase; BRAF, B-RAF proto-oncogene, serine/threonine kinase oncogene; EGFR, epidermal growth factor 
receptor; FISH, fluorescence in situ hybridization; FGFR1, fibroblast growth factor receptor type 1; HER2, human epidermal growth factor 
receptor type 2; IHC, immunohistochemistry; KRAS, Kirsten rat sarcoma viral oncogene homolog; MET, tyrosine-protein kinase MET/
hepatocyte growth factor receptor; PD-L1, programmed death-ligand 1; RET, proto-oncogene tyrosine-protein kinase receptor Ret; RNA, 
ribonucleic acid; ROS1, ROS proto-oncogene 1 receptor tyrosine kinase.
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Mutations in EGFR were detected in almost one fifth 
of patients (18%), a percentage that is comparable with 
that previously reported for Caucasian patients with lung 
adenocarcinoma (37,38). EGFR is the most important driver 
gene in NSCLC (37), and tumors bearing EGFR mutations 
can be treated with first-line targeted therapies, such as 
the tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, 
afatinib, and osimertinib, leading to higher response 
rates (55–78%) than with standard chemotherapy (39). 
In about 15% of our patients, the so-called gatekeeper 
T790M mutation in exon 20 was detected, which is 
considered the most common resistance mechanism to 
TKIs (40).
Mutations in KRAS were detected in 28% of patients, 
a population that, according to published data, has a 
poor prognosis. The percentage of KRAS mutations in 
our population is also comparable with that reported for 
Caucasian patients with lung adenocarcinoma, estimated 
at around 30% (41). The KRAS pathway links the EGFR 
pathway to cell proliferation and survival, and KRAS 
mutations, which are associated with former or current 
smokers (41), have been shown to mediate resistance 
to TKIs, being a negative predictive factor in advanced 
NSCLC (42). ALK translocations were detected in 
11% of patients included in the study. This percentage 
is somewhat higher than that previously published for 
NSCLC, ranging from 3% to 7.0% (43,44). The ALK 
fusion defines a distinct subpopulation of patients with 
lung adenocarcinoma who are highly responsive (57–74%) 
to ALK inhibitors such as crizotinib (45). It has been 
shown that EGFR, KRAS, and ALK molecular alterations 
are mutually exclusive events; nevertheless, they have 
been described in up to 2.7% of lung adenocarcinoma 
cases with concurrent molecular alterations (36). 
PD-L1 expression, which has been identified—although 
not without controversy—as a potential predictor of 
response to anti-PD-1 (e.g., pembrolizumab) and anti-
PD-L1 (e.g., durvalumab) monoclonal antibody therapy 
and also as a prognostic biomarker, was detected in nearly 
50% of patients in our cohort. A real-world study showed 
that, among patients with metastatic or recurrent NSCLC 
diagnosis eligible for the study, only 48% had one or more 
tests for PD-L1 determination, with 18% tested in 2015 
and 71% in 2017 (46). These findings are important, since 
there are effective first-line therapies to treat patients 
with NSCLC who overexpress PD-L1 (47). In the clinical 
setting, correctly identifying these patients is imperative.
Other biomarkers analyzed showed percentages of 
positivity roughly similar to those previously published in 
adenocarcinoma, although some variability was expected 
due to the low number of patients evaluated: ROS1 
rearrangements (observed vs. literature), 4.3% vs. 1–2%; 
MET amplification, 7.1% vs. 4–5%; RET fusions, 2.3% vs. 
1–2%; BRAF mutations, 3.3% vs. 1–3%; HER2 mutations, 
6.5% vs. 1.6–4%; and FGFR1 amplification, 7.7% vs. 3% 
(36,48).
Interestingly, the frequency of all these molecular 
alterations was similar when analyzed in the subgroup of 
patients with advanced stage IV disease. In this regard, a 
previous study by Pi et al. reported that early-stage and 
advanced-stage lung adenocarcinoma exhibited the same 
EGFR mutation frequencies and types (49). 
A possible limitation of the study could be the potential 
bias due to the data sources, perhaps with greater 
representation of patients recruited in large hospitals. 
However, the study has many advantages, such as the large 
number of patients included to date and the considerable 
number of sites involved, of all sizes and from virtually 
the entire national territory; also important is the fact that 
Spain has a National Health System with universal coverage 
and, thus, all patients follow the same diagnostic work-
up and have the same treatment opportunities, regardless 
of where they live or their income. A further advantage is 
that all patients have been recruited in a short-time period, 
allowing the comparison of treatments.
Conclusions
We believe that the TTR study accurately describes the 
clinical reality of lung cancer in Spain, including useful 
information with respect to demographic, clinical and 
molecular aspects that can be used to drive improvements 
in health care. In this sense, this type of studies should 
be extended to other European countries (50). Tobacco 
smoking, along with other environmental pollutants, 
remains the most important risk factor for lung cancer; 
social and political pressure to reduce tobacco consumption 
among the population should be reinforced, particularly 
among youth. 
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Table S1 Patient symptoms according to the initial stage of the disease
Symptoms
Total (n=6,574) Early disease (n=2,295) Advanced disease (n=4,279)
P value
n % n % n %
Unknown 1,174 17.9 435 37.1 739 62.9 <0.001
No 913 13.9 574 62.9 339 37.1
Yes 4,487 68.3 1,286 28.7 3,201 71.3
Cough 1,964 43.8 584 29.7 1,380 70.3 <0.001
Pain 1,606 35.8 353 22.0 1,253 78.0 <0.001
Dyspnoea 1,488 33.2 387 26.0 1,101 74.0 <0.001
Hemoptysis 671 15.0 265 39.5 406 60.5 0.009
Weight loss 1,184 26.4 241 20.4 943 79.6 <0.001
Anorexia 290 6.5 57 19.7 233 80.3 <0.001
Asthenia 396 8.8 97 24.5 299 75.5 <0.001
Others 1,448 32.3 367 25.3 1,081 74.7 <0.001
Table S2 Relationship between exposure to potential carcinogens and the initial stage of the disease
Probable carcinogen
Total (n=6,574) Early disease (n=2,295) Advanced disease (n=4,279)
P value
n % n % n %
Not listed/unknown 5,770 87.8 1,992 34.5 3,778 65.5 0.020
Related to asbestos 141 2.1 67 47.5 74 52.5
Related to arsenic 16 0.2 2 12.5 14 87.5
Radon/silica 38 0.6 18 47.4 20 52.6
Dyes 39 0.6 12 30.8 27 69.2
Paintings 105 1.6 40 38.1 65 61.9
Acrylonitrile 8 0.1 2 25.0 6 75.0
Diesel engine smoke 144 2.2 55 38.2 89 61.8
Others 313 4.8 107 34.2 206 65.8
Supplementary
Table S3 Relationship between personal and family history of cancer and the initial stage of the disease
History of cancer
Total (n=6,574) Early disease (n=2,295) Advanced disease (n=4,279)
P value
n % n % n %
Personal history of cancer <0.001
Unknown 807 12.3 249 30.9 558 69.1
No 4,799 73.0 1,585 33.0 3,214 67.0
Yes 968 14.7 461 47.6 507 52.4
Family history of cancer 0.902
Unknown 2,031 30.9 704 34.7 1,327 65.3
No 2,215 33.7 770 34.8 1,445 65.2
Yes 2,328 35.4 821 35.3 1,507 64.7
Table S4 Passive-smoking according to sex
Passive smoking
Total (n=6,600) Male sex (n=4,847) Female sex (n=1,753)
P value
n % n % n %
Unknown 4,686 71.0 3,511 74.9 1,175 25.1 <0.001
No 873 13.2 675 77.3 198 22.7
Yes 1,041 15.8 661 63.5 380 36.5
Table S5 Molecular profiling of stage IV tumors at diagnosis
Biomarker n %
Any biomarker
No 642 18.6
Yes 2,804 81.4
ALK (IHC)
Not performed 1,924 55.8
Performed 1,522 44.2
Negative 1,448 95.1
Positive 74 4.9
ALK (FISH)
Not performed 2,913 84.5
Performed 533 15.5
Not translocated 466 87.4
Translocated 67 12.6
ALK (RNA)
Not performed 3,407 98.9
Performed 39 1.1
Not detected 37 94.9
Detected 2 5.1
KRAS
Not performed 3,131 90.9
Performed 315 9.1
Not detected 203 64.4
Detected 85 27.0
BRAF
Not performed 3,111 90.3
Performed 335 9.7
Not detected 321 95.8
Detected 14 4.2
HER2 (mutated)
Not performed 3,428 99.5
Performed 18 0.5
Not detected 17 94.4
Detected 1 5.6
HER2 (IHC)
Not performed 3,431 99.6
Performed 15 0.4
Negative 14 93.3
Positive 1 6.7
HER2 (FISH)
Not performed 3,444 99.9
Performed 2 0.1
Negative 2 100.0
Positive 0 0.0
Positive 0 0.0
Table S5 (continued)
Table S5 (continued)
Biomarker n %
ROS1 (FISH)
Not performed 2,979 86.4
Performed 467 13.6
Not translocated 443 94.9
Translocated 24 5.1
FGFR1
Not performed 3,439 99.8
Performed 7 0.2
Not amplified 7 100.0
Amplified 0 0.0
PD-L1
Not performed 2,379 69.0
Performed 1,067 31.0
Unknown 447 41.9
Negative 535 50.1
Positive 85 8.0
RET
Not performed 3,437 99.7
Performed 9 0.3
Not translocated 9 100.0
Translocated 0 0.0
MET
Not performed 3,366 97.7
Performed 80 2.3
Negative 73 91.3
Overexpressed 1 1.3
Amplified 6 7.5
EGFR
Not performed 872 25.3
Performed 2,574 74.7
Unknown 8 0.3
Not mutated 2,043 79.4
Mutated 523 20.3
Exon-19 285 54.5
Exon-21 161 30.8
T790M (+) 84 16.1
T790M (–) 23 4.4
Other type 72 13.8
ALK, anaplastic lymphoma kinase; BRAF, B RAF proto-oncogene, 
serine/threonine kinase oncogene; EGFR, epidermal growth factor 
receptor; FISH, fluorescence in situ hybridization; FGFR1, fibroblast 
growth factor receptor type 1; HER2, human epidermal growth 
factor receptor type 2; IHC, immunohistochemistry; KRAS, Kirsten 
rat sarcoma viral oncogene homolog; MET, tyrosine-protein kinase 
MET/hepatocyte growth factor receptor; PD-L1, programmed 
death-ligand 1; RET, proto-oncogene tyrosine-protein kinase 
receptor Ret; RNA, ribonucleic acid; ROS1, ROS proto-oncogene 
1 receptor tyrosine kinase.
Table S6 Molecular profiling of stage IV tumors (adenocarcinoma only) according to year of diagnosis
Biomarker
All years (n=2,570) Unknown (n=323) ≤2012 (n=283) 2013–2014 (n=418) 2015–2016 (n=714) 2017–2018 (n=832)
P value
n % n % n % n % n % n %
ALK (IHC)
Not performed 1,219 47.4 214 66.3 196 69.3 230 55.0 286 40.1 293 35.2 –
Performed 1,351 52.6 109 33.7 87 30.7 188 45.0 428 59.9 539 64.8 <0.001
Negative 1,278 94.6 102 93.6 76 87.4 175 93.1 413 96.5 512 95.0 –
Positive 73 5.4 7 6.4 11 12.6 13 6.9 15 3.5 27 5.0 0.004
ALK (FISH)
Not performed 2,092 81.4 221 68.4 257 90.8 342 81.8 561 78.6 711 85.5 –
Performed 478 18.6 102 31.6 26 9.2 76 18.2 153 21.4 121 14.5 <0.001
Not translocated 413 86.4 101 99.0 20 76.9 59 77.6 128 83.7 105 86.8 –
Translocated 65 13.6 1 1.0 6 23.1 17 22.4 25 16.3 16 13.2 0.321
ALK (RNA)
Not performed 2,535 98.6 321 99.4 281 99.3 412 98.6 700 98.0 821 98.7 –
Performed 35 1.4 2 0.6 2 0.7 6 1.4 14 2.0 11 1.3 0.483
Not detected 33 94.3 2 100.0 1 50.0 5 83.3 14 100.0 11 100.0 –
Detected 2 5.7 0 0.0 1 50.0 1 16.7 0 0.0 0 0.0 –
ROS1 (FISH)
Not performed 2,153 83.8 282 87.3 264 93.3 362 86.6 585 81.9 660 79.3 –
Performed 417 16.2 41 12.7 19 6.7 56 13.4 129 18.1 172 20.7 <0.001
Not translocated 393 94.2 40 97.6 15 78.9 49 87.5 124 96.1 165 95.9 –
Translocated 24 5.8 1 2.4 4 21.1 7 12.5 5 3.9 7 4.1 –
EGFR
Not performed 286 11.1 69 21.4 43 15.2 54 12.9 54 7.6 66 7.9 –
Performed 2,284 88.9 254 78.6 240 84.8 364 87.1 660 92.4 766 92.1 <0.001
Unknown 7 0.3 0 0.0 0 0.0 0 0.0 1 0.2 6 0.8 –
Not mutated 1,774 77.7 203 79.9 183 76.3 275 75.5 519 78.6 594 77.5 –
Mutated 503 22.0 51 20.1 57 23.8 89 24.5 140 21.2 166 21.7 0.621
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; RNA, ribonucleic acid; ROS1, 
ROS proto-oncogene 1 receptor tyrosine kinase.
